SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, announced today that Evan M. Levine,
ADVENTRX's chief executive officer, is scheduled to present at the 2007
BIOCOM Investor Conference on November 2nd, 2007 at 9:30 a.m. Pacific Time
(12:30 p.m. Eastern Time). The conference takes place in San Diego at the
Marriott Del Mar hotel, October 31 - November 2, 2007.
The presentation will be webcast live via the "Investors" section of
the Company's web site at http://www.adventrx.com under "Events." The
webcast will be available for replay for 14 days and can be accessed
through the same link.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can be found
on the Company's web site at http://www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks and assumptions that, if they materialize or
do not prove to be accurate, could cause ADVENTRX's results to differ
materially from historical results or those expressed or implied by such
forward-looking statements. These risks and uncertainties include, but are
not limited to: the risk that ADVENTRX will be unable to raise sufficient
capital to fund the projects necessary to meet its anticipated or stated
goals and milestones; the ability to timely enroll subjects in and the
results of ADVENTRX's current and anticipated clinical trials; the
potential for ADVENTRX's product candidates to receive regulatory approval
for one or more indications on a timely basis or at all, and the uncertain
process of seeking regulatory approval; the market potential for ADVENTRX's
product candidates and ADVENTRX's ability to compete in those markets; and
other risks and uncertainties more fully described in ADVENTRX's press
releases and periodic filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange Commission are
available at http://www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date when made. ADVENTRX does not
intend to update any forward-looking statement, including as set forth in
this press release, to reflect events or circumstances arising after the
date on which it was made.
SOURCE ADVENTRX Pharmaceuticals, Inc.
 back to top
Related links:
http://www.adventrx.com
CONTACT:
Ioana C. Hone of ADVENTRX Pharmaceuticals,
+1-858-552-0866
|
